{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:25:57Z","timestamp":1791872757320,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Circular RNAs (circRNAs) mediate the infiltration of tumor-associated macrophages (TAMs) to facilitate carcinogenesis and development of various types of cancers. However, the role of circRNAs in regulating macrophages in prostate cancer (PCa) remains uncertain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Differentially expressed circRNAs in PCa were identified by RNA sequencing. The expression of circSMARCC1 was recognized and evaluated using fluorescence in situ hybridization and quantitative real-time PCR. The oncogenic role of circSMARCC1 in PCa tumor proliferation and metastasis was investigated through a series of in vitro and in vivo assays. Finally, Western blot, biotin-labeled RNA pulldown, luciferase assay, rescue experiments, and co-culture experiments with TAMs were conducted to reveal the mechanistic role of circSMARCC1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CircSMARCC1 was dramatically up-regulated in PCa cells, plasma and tissues. Overexpression of circSMARCC1 promotes tumor proliferation and metastasis both in vitro and in vivo, whereas knockdown of circSMARCC1 exerts the opposite effects. Mechanistically, circSMARCC1 regulates the expression of CC-chemokine ligand 20 (CCL20) via sponging miR-1322 and activate PI3K-Akt signaling pathway involved in the proliferation and epithelial mesenchymal transformation. More importantly, high expression of circSMARCC1 was positively associated with colonization of CD68<jats:sup>+<\/jats:sup>\/CD163<jats:sup>+<\/jats:sup>\/CD206<jats:sup>+<\/jats:sup> TAMs in tumor microenvironment. In addition, overexpression of circSMARCC1 facilitates the expression of CD163 in macrophages through the CCL20-CCR6 axis, induces TAMs infiltration and M2 polarization, thereby leading to PCa progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CircSMARCC1 up-regulates the chemokine CCL20 secretion by sponging miR-1322, which is involved in the crosstalk between tumor cells and TAMs by targeting CCL20\/CCR6 signaling to promote progression of PCa.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-022-01630-9","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T03:31:37Z","timestamp":1662003097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322\/CCL20\/CCR6 signaling"],"prefix":"10.1186","volume":"21","author":[{"given":"Tao","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du-jiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-jun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Lu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-zhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqian","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Han","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-8077","authenticated-orcid":false,"given":"Shan-Chao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"1630_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1630_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1158\/1055-9965.EPI-19-0412","volume":"29","author":"KH Kensler","year":"2020","unstructured":"Kensler KH, Rebbeck TR. Cancer Progress and priorities: prostate Cancer. Cancer Epidemiol Biomark Prev. 2020;29:267\u201377.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1630_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","volume":"71","author":"X Li","year":"2018","unstructured":"Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71:428\u201342.","journal-title":"Mol Cell"},{"key":"1630_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475\u201390.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1630_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-021-01333-7","volume":"20","author":"P Shen","year":"2021","unstructured":"Shen P, Yang T, Chen Q, Yuan H, Wu P, Cai B, et al. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Mol Cancer. 2021;20:51.","journal-title":"Mol Cancer"},{"key":"1630_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cmet.2019.05.009","volume":"30","author":"Q Li","year":"2019","unstructured":"Li Q, Wang Y, Wu S, Zhou Z, Ding X, Shi R, et al. CircACC1 regulates assembly and activation of AMPK complex under metabolic stress. Cell Metab. 2019;30:157\u2013173.e157.","journal-title":"Cell Metab"},{"key":"1630_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256\u201364.","journal-title":"Nat Struct Mol Biol"},{"key":"1630_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-020-1135-7","volume":"19","author":"M Lei","year":"2020","unstructured":"Lei M, Zheng G, Ning Q, Zheng J, Dong D. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19:30.","journal-title":"Mol Cancer"},{"key":"1630_CR9","doi-asserted-by":"publisher","first-page":"19908","DOI":"10.18632\/aging.203408","volume":"13","author":"X Xie","year":"2021","unstructured":"Xie X, Sun FK, Huang X, Wang CH, Dai J, Zhao JP, et al. A circular RNA, circSMARCA5, inhibits prostate cancer proliferative, migrative, and invasive capabilities via the miR-181b-5p\/miR-17-3p-TIMP3 axis. Aging (Albany NY). 2021;13:19908\u201319.","journal-title":"Aging (Albany NY)"},{"key":"1630_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-021-01480-x","volume":"21","author":"Y-Z Yu","year":"2022","unstructured":"Yu Y-Z, Lv D-J, Wang C, Song X-L, Xie T, Wang T, et al. Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p. Mol Cancer. 2022;21:12.","journal-title":"Mol Cancer"},{"key":"1630_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.canlet.2021.10.021","volume":"524","author":"S Wang","year":"2022","unstructured":"Wang S, Chao F, Zhang C, Han D, Xu G, Chen G. Circular RNA circPFKP promotes cell proliferation by activating IMPDH2 in prostate cancer. Cancer Lett. 2022;524:109\u201320.","journal-title":"Cancer Lett"},{"key":"1630_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309\u201322.","journal-title":"Cancer Cell"},{"key":"1630_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.intimp.2011.12.011","volume":"12","author":"Y Ye","year":"2012","unstructured":"Ye Y, Huang X, Zhang Y, Lai X, Wu X, Zeng X, et al. Calcium influx blocked by SK&F 96365 modulates the LPS plus IFN-\u03b3-induced inflammatory response in murine peritoneal macrophages. Int Immunopharmacol. 2012;12:384\u201393.","journal-title":"Int Immunopharmacol"},{"key":"1630_CR14","doi-asserted-by":"publisher","first-page":"E1211","DOI":"10.1073\/pnas.1321347111","volume":"111","author":"X Xiao","year":"2014","unstructured":"Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc Natl Acad Sci U S A. 2014;111:E1211\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1630_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10549-010-1154-y","volume":"128","author":"MJ Campbell","year":"2011","unstructured":"Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011;128:703\u201311.","journal-title":"Breast Cancer Res Treat"},{"key":"1630_CR16","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/gutjnl-2015-309193","volume":"65","author":"G Di Caro","year":"2016","unstructured":"Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut. 2016;65:1710\u201320.","journal-title":"Gut"},{"key":"1630_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1046\/j.1442-2042.2000.00190.x","volume":"7","author":"T Hanada","year":"2000","unstructured":"Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000;7:263\u20139.","journal-title":"Int J Urol"},{"key":"1630_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4149\/neo_2019_190213N116","volume":"67","author":"H Jiang","year":"2020","unstructured":"Jiang H, Lv DJ, Song XL, Wang C, Yu YZ, Zhao SC. Upregulated circZMIZ1 promotes the proliferation of prostate cancer cells and is a valuable marker in plasma. Neoplasma. 2020;67:68\u201377.","journal-title":"Neoplasma"},{"key":"1630_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-019-0943-0","volume":"18","author":"L Chen","year":"2019","unstructured":"Chen L, Nan A, Zhang N, Jia Y, Li X, Ling Y, et al. Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. Mol Cancer. 2019;18:13.","journal-title":"Mol Cancer"},{"key":"1630_CR20","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.7150\/thno.33972","volume":"9","author":"DJ Lv","year":"2019","unstructured":"Lv DJ, Song XL, Huang B, Yu YZ, Shu FP, Wang C, et al. HMGB1 promotes prostate Cancer development and metastasis by interacting with Brahma-related gene 1 and activating the Akt signaling pathway. Theranostics. 2019;9:5166\u201382.","journal-title":"Theranostics"},{"key":"1630_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cell.2019.01.025","volume":"176","author":"S Chen","year":"2019","unstructured":"Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, et al. Widespread and functional RNA circularization in localized prostate Cancer. Cell. 2019;176:831\u2013843.e822.","journal-title":"Cell"},{"key":"1630_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.12.024","volume":"472","author":"W Liu","year":"2020","unstructured":"Liu W, Wang W, Wang X, Xu C, Zhang N, Di W. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020;472:59\u201369.","journal-title":"Cancer Lett"},{"key":"1630_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559\u201372.","journal-title":"Nat Rev Immunol"},{"key":"1630_CR24","doi-asserted-by":"publisher","first-page":"e1189052","DOI":"10.1080\/2162402X.2016.1189052","volume":"5","author":"B Nandi","year":"2016","unstructured":"Nandi B, Shapiro M, Samur MK, Pai C, Frank NY, Yoon C, et al. Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. Oncoimmunology. 2016;5:e1189052.","journal-title":"Oncoimmunology"},{"key":"1630_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-015-0394-1","volume":"14","author":"ST Boyle","year":"2015","unstructured":"Boyle ST, Faulkner JW, McColl SR, Kochetkova M. The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages. Mol Cancer. 2015;14:115.","journal-title":"Mol Cancer"},{"key":"1630_CR26","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021;39:1464\u20131478.e1468.","journal-title":"Cancer Cell"},{"key":"1630_CR27","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"CE Hughes","year":"2018","unstructured":"Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285:2944\u201371.","journal-title":"FEBS J"},{"key":"1630_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1359-6101(03)00049-2","volume":"14","author":"E Schutyser","year":"2003","unstructured":"Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409\u201326.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1630_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18:64.","journal-title":"Mol Cancer"},{"key":"1630_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/280339a0","volume":"280","author":"MT Hsu","year":"1979","unstructured":"Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;280:339\u201340.","journal-title":"Nature"},{"key":"1630_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","volume":"19","author":"WY Zhou","year":"2020","unstructured":"Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19:172.","journal-title":"Mol Cancer"},{"key":"1630_CR32","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hep.31068","volume":"72","author":"ZQ Hu","year":"2020","unstructured":"Hu ZQ, Zhou SL, Li J, Zhou ZJ, Wang PC, Xin HY, et al. Circular RNA sequencing identifies CircASAP1 as a key regulator in hepatocellular carcinoma metastasis. Hepatology. 2020;72:906\u201322.","journal-title":"Hepatology"},{"key":"1630_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13046-020-01556-4","volume":"39","author":"Y Xu","year":"2020","unstructured":"Xu Y, Yu J, Huang Z, Fu B, Tao Y, Qi X, et al. Circular RNA hsa_circ_0000326 acts as a miR-338-3p sponge to facilitate lung adenocarcinoma progression. J Exp Clin Cancer Res. 2020;39:57.","journal-title":"J Exp Clin Cancer Res"},{"key":"1630_CR34","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1002\/jcb.29672","volume":"121","author":"M Zhao","year":"2020","unstructured":"Zhao M, Dong G, Meng Q, Lin S, Li X. Circ-HOMER1 enhances the inhibition of miR-1322 on CXCL6 to regulate the growth and aggressiveness of hepatocellular carcinoma cells. J Cell Biochem. 2020;121:4440\u20139.","journal-title":"J Cell Biochem"},{"key":"1630_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40364-021-00262-3","volume":"9","author":"J Wu","year":"2021","unstructured":"Wu J, Zheng C, Wang Y, Yang Z, Li C, Fang W, et al. LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322\/miR-1972\/miR-324-3p-SIRT5 axis in lung adenocarcinoma. Biomark Res. 2021;9:9.","journal-title":"Biomark Res"},{"key":"1630_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-014-0045-y","volume":"12","author":"R Chu","year":"2014","unstructured":"Chu R, Mo G, Duan Z, Huang M, Chang J, Li X, et al. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal. 2014;12:45.","journal-title":"Cell Commun Signal"},{"key":"1630_CR37","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2012.09.018","volume":"61","author":"HW Khella","year":"2013","unstructured":"Khella HW, Bakhet M, Lichner Z, Romaschin AD, Jewett MA, Yousef GM. MicroRNAs in kidney disease: an emerging understanding. Am J Kidney Dis. 2013;61:798\u2013808.","journal-title":"Am J Kidney Dis"},{"key":"1630_CR38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1365-3083.2006.001766.x","volume":"63","author":"C Rubie","year":"2006","unstructured":"Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, et al. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand J Immunol. 2006;63:468\u201377.","journal-title":"Scand J Immunol"},{"key":"1630_CR39","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<650::AID-IJC23>3.0.CO;2-#","volume":"81","author":"J Kleeff","year":"1999","unstructured":"Kleeff J, Kusama T, Rossi DL, Ishiwata T, Maruyama H, Friess H, et al. Detection and localization of Mip-3alpha\/LARC\/exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer. 1999;81:650\u20137.","journal-title":"Int J Cancer"},{"key":"1630_CR40","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/jcmm.12781","volume":"20","author":"B Wang","year":"2016","unstructured":"Wang B, Shi L, Sun X, Wang L, Wang X, Chen C. Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway. J Cell Mol Med. 2016;20:920\u20139.","journal-title":"J Cell Mol Med"},{"key":"1630_CR41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/00130404-200411000-00007","volume":"10","author":"TF Kimsey","year":"2004","unstructured":"Kimsey TF, Campbell AS, Albo D, Wilson M, Wang TN. Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J. 2004;10:374\u201380.","journal-title":"Cancer J"},{"key":"1630_CR42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.bbrc.2004.07.207","volume":"322","author":"H Fujii","year":"2004","unstructured":"Fujii H, Itoh Y, Yamaguchi K, Yamauchi N, Harano Y, Nakajima T, et al. Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44\/42 MAPK in vitro. Biochem Biophys Res Commun. 2004;322:1052\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1630_CR43","doi-asserted-by":"publisher","first-page":"e2005869","DOI":"10.1371\/journal.pbio.2005869","volume":"16","author":"W Chen","year":"2018","unstructured":"Chen W, Qin Y, Wang D, Zhou L, Liu Y, Chen S, et al. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018;16:e2005869.","journal-title":"PLoS Biol"},{"key":"1630_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249\u201362.","journal-title":"Cancer Cell"},{"key":"1630_CR45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","volume":"95","author":"SM Zeisberger","year":"2006","unstructured":"Zeisberger SM, Odermatt B, Marty C, Zehnder-Fj\u00e4llman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95:272\u201381.","journal-title":"Br J Cancer"},{"key":"1630_CR46","doi-asserted-by":"crossref","unstructured":"Kadomoto S, Izumi K, Mizokami A. Roles of CCL2-CCR2 Axis in the tumor microenvironment. Int J Mol Sci. 2021;22(16):8530.","DOI":"10.3390\/ijms22168530"},{"key":"1630_CR47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-Centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651\u201362.","journal-title":"Lancet Oncol"},{"key":"1630_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2490-14-12","volume":"14","author":"D Wong","year":"2014","unstructured":"Wong D, Kandagatla P, Korz W, Chinni SR. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol. 2014;14:12.","journal-title":"BMC Urol"},{"key":"1630_CR49","doi-asserted-by":"publisher","first-page":"111588","DOI":"10.1016\/j.yexcr.2019.111588","volume":"384","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Xia J, Wang Y, Zhang J, Ji C, Cong R, et al. Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy. Exp Cell Res. 2019;384:111588.","journal-title":"Exp Cell Res"},{"key":"1630_CR50","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/j.1464-410X.2010.09804.x","volume":"107","author":"N Nonomura","year":"2011","unstructured":"Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011;107:1918\u201322.","journal-title":"BJU Int"},{"key":"1630_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/path.5757","volume":"255","author":"LB Andersen","year":"2021","unstructured":"Andersen LB, N\u00f8rgaard M, Rasmussen M, Freds\u00f8e J, Borre M, Ulh\u00f8i BP, et al. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol. 2021;255:155\u201365.","journal-title":"J Pathol"},{"key":"1630_CR52","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3892\/ol.2015.3400","volume":"10","author":"W Hu","year":"2015","unstructured":"Hu W, Qian Y, Yu F, Liu W, Wu Y, Fang X, et al. Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma. Oncol Lett. 2015;10:1390\u20136.","journal-title":"Oncol Lett"},{"key":"1630_CR53","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-020-2435-y","volume":"11","author":"R Huang","year":"2020","unstructured":"Huang R, Wang S, Wang N, Zheng Y, Zhou J, Yang B, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating \u03b2-catenin\/STAT3 signaling. Cell Death Dis. 2020;11:234.","journal-title":"Cell Death Dis"},{"key":"1630_CR54","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00262-014-1591-2","volume":"63","author":"M Idorn","year":"2014","unstructured":"Idorn M, K\u00f8llgaard T, Kongsted P, Sengel\u00f8v L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63:1177\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"1630_CR55","doi-asserted-by":"crossref","unstructured":"Martori C, Sanchez-Moral L, Paul T, Pardo JC, Font A, Ruiz de Porras V, et al. Macrophages as a therapeutic target in metastatic prostate Cancer: a way to overcome immunotherapy resistance? Cancers (Basel). 2022;14(2):440.","DOI":"10.3390\/cancers14020440"},{"key":"1630_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","volume":"36","author":"W Su","year":"2019","unstructured":"Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, et al. The Polycomb repressor complex 1 drives double-negative prostate Cancer metastasis by coordinating Stemness and immune suppression. Cancer Cell. 2019;36:139\u2013155.e110.","journal-title":"Cancer Cell"},{"key":"1630_CR57","doi-asserted-by":"publisher","first-page":"10908","DOI":"10.7150\/thno.48264","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Han X, Yang L, Fu J, Sun C, Huang S, et al. Circular RNA circPPM1F modulates M1 macrophage activation and pancreatic islet inflammation in type 1 diabetes mellitus. Theranostics. 2020;10:10908\u201324.","journal-title":"Theranostics"},{"key":"1630_CR58","doi-asserted-by":"publisher","first-page":"8920","DOI":"10.1080\/21655979.2021.1989999","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Cheng F, Rong G, Tang Z, Gui B. Circular RNA hsa_circ_0005567 overexpression promotes M2 type macrophage polarization through miR-492\/SOCS2 axis to inhibit osteoarthritis progression. Bioengineered. 2021;12:8920\u201330.","journal-title":"Bioengineered"}],"updated-by":[{"DOI":"10.1186\/s12943-023-01881-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01630-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01630-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01630-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T09:03:40Z","timestamp":1698051820000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01630-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01630-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12943-023-01881-0","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-023-01881-0","URL":"https:\/\/doi.org\/10.1186\/s12943-023-01881-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were approved by the Medical Ethics Committee of Nanfang Hospital of Southern Medical University (NFEC-2022-083) and performed in accordance with the relevant guidelines and regulations. Written informed consents were obtained from all patients. All experimental animal procedures were authorized by the Nanfang Hospital Animal Ethics Committee of Southern Medical University (NFYY-2020-0132).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}